|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, January 21, 2017 ) The Report, "Small interfering RNA (siRNA) Therapeutics-Competitive Landscape, Technology and Pipeline Insights, 2016" depicts the current pipeline scenario of siRNA therapies under development. Many targets which were difficult to reach by traditional small-molecule and protein have been identified by therapeutics based on RNA interference (RNAi). RNA interference (RNAi), a process in recovery Phase, is still keeping the expectations of the many mid Pharma companies at a higher end with blockbuster deals and adequate delivery technologies.
This report analysis the current frontrunners in siRNA therapies with leading technologies and major acquisitions and deals seen in past 3 years. Report highlights the 16 different types of technologies that have been used lately to enhance the siRNA development in different stages of development.
There are 15+ active companies dealing with 85+ siRNA therapies. Mostly siRNA is being studied for oncology area with 27 siRNA therapies under development by major pharma companies followed by 14 therapies for infectious diseases and 8 siRNA therapies in Ophthalmology.
For More Information About This Report: http://www.reportsweb.com/small-interfering-rna-sirna-therapeutics-competitive-landscape-technology-and-pipeline-insights-2016
Report Scope:
-Coverage of global siRNA therapies under development across the globe
-Competitive landscape of investigational products for key players and key therapy areas
-The new siRNA report includes emerging technologies, drivers, barriers and eminent therapy areas focused by major companies.
-Detailed information on product description and related stage of development, the mode of therapy, mechanism of action, development partner and technology information.
-Report has highlighted the major collaborations, deals and acquisitions done by pharma companies to enrich their siRNA pipeline.
-Report analyzes the different emerging delivery technologies by companies and products under development.
Request Sample Copy At: http://www.reportsweb.com/inquiry&RW0001153597/sample
Reason to Buy:
-The siRNA report covers complete Pipeline intelligence and understanding over therapeutics development for siRNA.
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
-Identify and understand important and diverse types of therapeutics under development for siRNA
-The siRNA report helps to develop a better understanding of the emerging technologies by the recent acquisitions which are driving the siRNA market
-Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
-Devise corrective measures for pipeline projects by understanding siRNA pipeline in-depth
-Identifying the upcoming leaders in the siRNA market in the coming year
Inquire for Report At: http://www.reportsweb.com/inquiry&RW0001153597/buying
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
